Axicabtagene ciloleucel (axi-cel CAR-T) for relapsed/refractory HGBL-DH
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | None declared |
|---|
| ID | REG-CAR-T-AXICEL-HGBL |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-DLBCL-2024 SRC-NCCN-BCELL-2025 |
Notes
ZUMA-1 (Locke 2019): axi-cel in r/r aggressive B-NHL — CR ~58%, durable response ~40% at 24 mo. ZUMA-7 (Locke 2022, NEJM): superior to standard salvage + autoSCT in early-relapse/primary-refractory. CRS + ICANS toxicity require certified CAR-T center.
Used By
Indication
IND-HGBL-DH-2L-CART-AXICEL- IND-HGBL-DH-2L-CART-AXICEL